Sign In
Buy ABBV
$227.23
+2.30 (+1.02%)
At Close: Jun 05, 2026
"Blockbuster Status": 3 Bios to Buy and Hold
03:47pm, Wednesday, 13'th Sep 2023
The biotech sector is notorious for its sky-high R&D costs, regulatory hurdles, and lengthy timelines to bring a drug to market. Stock Strategist Andrew Rocco unveils 3 biotech stocks that have broken
2 Undervalued Dividend Stocks to Buy Now
09:30am, Wednesday, 13'th Sep 2023
Top-shelf dividend stocks tend to trade at hefty premiums. Amgen and Bristol Myers Squibb are two clear exceptions to this general rule of thumb.
High Yield, Low Beta Stocks to Buy for the Next Market Meltdown
07:10am, Tuesday, 12'th Sep 2023
The market's fear indicator, the VIX index, is bobbing along at long-term lows and gives little indication of a looming correction, but investors should assume one is brewing. The index is down at its
4 Factor Dividend Growth Portfolio - Closing In On A Historic First Year
03:20pm, Thursday, 07'th Sep 2023
The 4-factor dividend growth portfolio is a strategy that leverages the stock selection process of Schwab U.S. Dividend Equity ETF, with a few minor twists. The portfolio fell by 0.57% in August, outp
3 Biotech Stocks to Invest In for Big-Time, Long-Term Gains
06:35pm, Tuesday, 05'th Sep 2023
In the grand tapestry of the investment world, one thread that continues to shine is biotech stocks to buy and hold. It's no secret that delving into biotech investments can be incredibly challenging,
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
10:31am, Tuesday, 05'th Sep 2023
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
AbbVie Unleashed: 4% Yield, Potentially 40% Undervalued
08:19am, Monday, 04'th Sep 2023
AbbVie has shown resilience and strength despite the patent loss of its best-selling drug, Humira. The company has reported impressive earnings, robust sales in various segments, and a promising pipel
AbbVie: Balance Is Everything
01:12am, Monday, 04'th Sep 2023
AbbVie's future growth depends on improving its balance of drugs offered, in contrast to its Humira-dependent first decade. Skyrizi and Rinvoq should offset the decline in Humira sales, but further gr
The 3 Most Promising Biotech Stocks to Own Now
05:42am, Thursday, 31'st Aug 2023
Despite polls showing most Americans are unhappy with the state of the economy, President Biden has defended his policies with claims he is improving the finances and living standards of minority vote
Buy Ratings For 5 September Dividend Kings; Watch 4 More
03:44pm, Wednesday, 30'th Aug 2023
"There is only one-criterion to be included among the Dividend Kings: a publicly-traded company must increase its total fiscal-year dividend-payout for a minimum of 50 consecutive-years."--Dogs of the
A Significant Reversal is in Sight for These 5 Med Tech Companies
09:32am, Wednesday, 30'th Aug 2023
Med tech has been on the skids for no fault of its own. It's not the industry's fault that price action was driven to a frothy bubble by COVID-inspired trading outlooks or that the market has normaliz
Now or Never: 7 Blue-Chip Stocks Offering a Once-in-a-Lifetime Opportunity
01:50pm, Tuesday, 29'th Aug 2023
Financial opportunities are as abundant as they are volatile. Seizing a selected group of blue-chip stocks to buy could lead to unparalleled investor growth.
Ranking 5 Dividend Growth Stocks From Highest To Lowest Quality
09:48am, Tuesday, 29'th Aug 2023
The article ranks 5 dividend growth stocks based on their quality, focusing on factors such as balance sheet, management, growth, and stability. The Home Depot is ranked as a "MUST OWN" stock due to i
Nearing Retirement? These Stocks Will Pay You For Life
09:45am, Tuesday, 29'th Aug 2023
Drugmakers are often great dividend payers, and AbbVie and Gilead are among the best. AbbVie sales are currently dropping, but that shouldn't last for too long.
Merck, Amgen, AbbVie products among first 10 drugs selected for Medicare price negotiations
07:50am, Tuesday, 29'th Aug 2023
Medicare on Tuesday announced the first 10 drugs selected for price negotiations, launching a historic and highly contentious process with big implications for pharmaceutical companies, taxpayers and
